OrbiMed secures 3 billion dollars across healthcare private equity funds
Healthcare investment manager OrbiMed raised 3 billion US dollars in capital commitments across two new funds OrbiMed Private Investments X and OrbiMed Asia Partners VI
New York, October 15, 2026 - OrbiMed, a prominent global healthcare investment firm, has announced the successful fundraising of $3 billion for two new private equity funds: OrbiMed Private Investments X and OrbiMed Asia Partners VI. The OrbiMed Private Investments X raised funds over $1.9 billion for investing in life sciences venture capital opportunities in the United States and Europe.
Meanwhile, OrbiMed Asia Partners VI garnered over $1 billion for investing in healthcare growth equity and venture capital prospects across Asia. The funds' aim is to cultivate leading healthcare companies focused on biopharmaceuticals, medical devices, diagnostics, and technology-driven healthcare services. Carl Gordon, a managing partner of OrbiMed, expressed excitement about these investments, stating that the current era presents unprecedented opportunities for life sciences innovation.
He highlighted advancements in AI, a surge in novel therapeutic approaches, and China's growing role as a biotechnology leader as contributing factors. OrbiMed, led by 20 partners and backed by a team of over 150 professionals skilled in company incubation, strategy, operations, and finance, operates from 12 global locations across significant healthcare markets.
The firm has received backing from diverse investors, including medical institutions, university endowments, foundations, pension funds, sovereign wealth funds, and family offices.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
